JFG
NTLA icon

Jefferies Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Jefferies Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69M Buy
+132,000
New +$1.68M 0.01% 695
2024
Q3 		– Sell
-10,000
Closed -$224K – 1661
2024
Q2 		$224K Buy
+10,000
New +$238K ﹤0.01% 1202

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jefferies Financial Group's NTLA Position: Q1 2026 in Review

Jefferies Financial Group opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 1,000 shares worth $12.8K. The stake represents ﹤0.01% of the portfolio and ranks #1683 among its holdings. This is a return to the name: Jefferies Financial Group previously reported a position in NTLA as recently as Q2 2024.

Jefferies Financial Group first reported a position in NTLA in Q2 2024 and has held it in 2 quarters since. The position peaked at $15.7K in Q2 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Jefferies Financial Group held 1,000 shares of Intellia Therapeutics worth $12.8K as of Q1 2026.
  • Intellia Therapeutics was a new Jefferies Financial Group position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1683 holding.
  • Jefferies Financial Group first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Jefferies Financial Group's Intellia Therapeutics position peaked at $15.7K in Q2 2024.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.